ScripIncyte Corporation reported positive topline results from the Phase III inMIND clinical trial of its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in relapsed or refractory follicular lymp
ScripMerck & Co., Inc. is getting into the well-trodden space of bispecific antibodies by acquiring CN201, a CD19xCD3-directed candidate, from a Chinese biotech company. The Rahway, NJ-based drug maker sa
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Curon Picks Up China-Plus Rights to Rhi